Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)

By sjmartinez • July 5, 2024

Clark VC, Strange C, Strnad P, Sanchez AJ, Kwo P, Pereira VM, van Hoek B, Barjaktarevic I, Corsico AG, Pons M, Goldklang M, Gray M, Kuhn B, Vargas HE, Vierling JM, Vuppalanchi R, Brantly M, Kappe N, Chang T, Schluep T, Zhou R, Hamilton J, San Martin J, Loomba R. Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA). Gastroenterology. 2024 Jul 2:S0016-5085(24)05181-3. doi: 10.1053/j.gastro.2024.06.028. Epub ahead of print. PMID: 38964420.

Tags: AAT, alpha-1 antitrypsin deficiency, Fazirsiran, Liver disease, Publications, Pulmonary, Critical Care & Sleep Medicine, Z-AAT

Human papillomavirus vaccination in rural Malawi: Identifying factors associated with vaccine uptake using a community-based household survey

Moucheraud C, Kalande P, Chibaka S, Phiri K, Makwaya A, Duah M, Li M, Liu M, Hoffman RM, Phiri S. Human papillomavirus vaccination in rural[...]

Outcomes Following Minimally Invasive Surgery for Intracerebral Hemorrhage in the AHA Get With The Guidelines Registry

Murthy SB, Zhang C, Garton ALA, Mac Grory B, Shah S, Fonarow GC, Schwamm LH, Bhatt DL, Smith EE, Falcone GJ, Payabvash S, Ziai WC,[...]

A randomized controlled trial of meditation and health education on carotid intima-media thickness and major adverse cardiovascular events in Black men and women

Norris KC, Salerno J, Bairey Merz CN, Kaushik V, Gelleta S, Castillo A, Nidich S, Gaylord-King C, Schneider RH. A randomized controlled trial of meditation[...]